AOD-9604 is a modified peptide fragment of human growth hormone (HGH), specifically the 176–191 amino acid sequence responsible for fat metabolism. Unlike full-length HGH, AOD-9604 focuses exclusively on stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat formation), without the unwanted side effects commonly associated with growth hormone.

Ozempic (Semaglutide)

Ozempic (Semaglutide) is a once-weekly injectable GLP-1 receptor agonist originally designed for managing type 2 diabetes. It has gained widespread use for weight loss and appetite suppression, making it a powerful tool for fat reduction and metabolic optimization.